Angiotensin-converting Enzyme Inhibitor

نویسنده

  • ROBERT A. KLONER
چکیده

The effects of angiotensin-converting enzyme inhibitor (CEI) SQ14225 on infarct size and regional myocardial blood flow were studied in 21 anesthetized dogs subjected to 6 hours of coronary occlusion. An area of myocardium at risk of necrosis was determined in vivo after 15 minutes of coronary occlusion but before CEI treatment (AR1) using an autoradiographic technique and after treatment after 6 hours of coronary occlusion (AR2) using a fluorescent dye technique. An in vitro area at risk (AR8), which measures coronary bed size, was determined by injecting Monastral dye postmortem. Infarct size was determined by planimetry of unstained myocardium after incubating heart slices in triphenyltetrazolium chloride. Regional myocardial blood flow (RMBF) was measured by injecting tracer microspheres simultaneously with measurements of AR1 and AR2. In 11 saline-treated control dogs (group A), infarct size averaged 93 ± 8% of AR1, 96 i 2% of AR2 and 75 ± 6% of AR9, respectively. In 10 dogs treated with CEI (0.25 mg/kg/hour) between 30 minutes and 6 hours after coronary occlusion (group B), infarct size was smaller and averaged 68 ± 5% of AR1 (p < 0.01), 79 ± 5% of AR2 (p < 0.005), and 57 ± 7% of AR3 (p < 0.05). RMBF in the ischemic zone remained constant in group A but increased by 62 ± 26% in group B (p < 0.025). In group B, mean arterial pressure decreased from 115 ± 6 to 103 ± 7 mm Hg (p < 0.025) between 30 minutes and 6 hours after coronary occlusion and left atrial pressure decreased from 9.0 ± 1.8 to 5.7 ± 0.8 mm Hg (p < 0.0025). These measurements did not change in group A. Thus, CEI is potent in reducing infarct size in the dog after coronary occlusion. It may act by increasing collateral flow to the ischemic zone and reducing afterload.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Serum Angiotensin Converting Enzyme in Patients with Psoriasis

Background: Controversial data concerning the elevation of serum angiotensin-converting enzyme in psoriasis are reported in the literature. In order to verify whether this abnormality exists in Iranian patients, we performed this study. Method: Serum angiotensin-converting enzyme level was measured in 40 psoriatics. According to clinical forms of psoriasis, patients were further divided into th...

متن کامل

P23: The Effects of Captopril, as Angiotensin Converting Enzyme Inhibitor, on LPS-Induced Systemic Inflammation

It has been shown that the renin-angiotensin system (RAS) plays key roles in the inflammation process. Imbalance in the oxidant-antioxidant system is one of the major causes of inflammation. In the present study, the effects of captopril on total and differential WBC, oxidative stress in systemic inflammation produced by lipopolysaccharide (LPS) were investigated. The rats were divided to: cont...

متن کامل

The Effect of Enalapril, an Angiotensin Converting Enzyme Inhibitor, on Diabetic Neuropathy: A Double Blind Random–Allocated Study

OBJECTIVE: Diabetes mellitus is one of the most common endocrine diseases with micro-vascular complications and is a common cause of polyneuropathy. We studied the effect of enalapril on electrophysiologic criteria and clinical symptoms of patients with type II diabetes and sensory neuropathy. MATERIALS AND METHODS: A double blind study was conducted on 45 Patients with type II diabetes and ne...

متن کامل

Inhibition of Angiotensin-Converting Enzyme Reduces Cerebral Infarction Size in Experimental-Induced Focal Cerebral Ischemia in the Rat

Background: The role of Renin Angiotensin System (RAS) in ischemic/reperfusion (I/R) injuries is not fully elucidated. Furthermore, it is not clear whether inhibition of RAS by Angiotensin-Converting Enzyme (ACE) inhibitors has beneficial effects in terms of protecting the brain from I/R injuries. In this study enalapril is used as an ACE inhibitor to evaluate the role of RAS in I/R injuries in...

متن کامل

Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor associated angioedema.

Angioedema is a potentially life-threatening adverse effect of angiotensin-converting enzyme inhibitors. Bradykinin and substance P, substrates of angiotensin-converting enzyme, increase vascular permeability and cause tissue edema in animals. Studies indicate that amino-terminal degradation of these peptides, by aminopeptidase P and dipeptidyl peptidase IV, may be impaired in individuals with ...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2005